Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Novo's semaglutide shows promise in curbing alcohol use disorder, according to data published in JAMA Psychiatry. This supports the use of GLP-1 receptor agonists for addictive disorders. Meanwhile, the Trump administration is considering job cuts at the FDA. This could potentially lead to uncertainty and delays in regulatory reviews.In other news, Sanofi is facing a $250 million impairment after scrapping a J&J-partnered E. coli vaccine. Roche's Evrysdi has become the first pill cleared for spinal muscular atrophy. Pfizer has expanded the label for Adcetris to include non-Hodgkin lymphomas.Additionally, Newleos Therapeutics has raised $93.5 million to advance neuropsychiatric drugs from Roche's pipeline. All this information was shared by BioSpace, a platform that provides updates on the biotech and pharmaceutical industry.